“Cost Per Responder Analysis of Guselkumab versus Adalimumab using Efficacy Results fromm a Head-to-Head Clinical Trial in Patients with Moderate to Severe Plaque Psoriasis”, J of Skin, vol. 1, no. 3.1, p. s6, Oct. 2017, doi: 10.25251/skin.1.supp.5.